AbbVie Inc. (ABBV)

US — Healthcare Sector
Peers: MRK  PFE  LLY  BMY  JNJ  AMGN  GILD 

Automate Your Wheel Strategy on ABBV

With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ABBV
  • Rev/Share 32.4474
  • Book/Share 0.8269
  • PB 237.3353
  • Debt/Equity 49.2176
  • CurrentRatio 0.7602
  • ROIC 0.1793

 

  • MktCap 336711168000.0
  • FreeCF/Share 8.7019
  • PFCF 21.8857
  • PE 80.3376
  • Debt/Assets 0.5133
  • DivYield 0.0335
  • ROE 0.9559

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade ABBV Citigroup Buy Neutral -- $205 May 14, 2025
Initiation ABBV Cantor Fitzgerald -- Overweight -- $210 April 22, 2025
Resumed ABBV BofA Securities -- Neutral -- $191 Dec. 10, 2024
Downgrade ABBV Daiwa Securities Outperform Neutral -- $180 Dec. 5, 2024
Initiation ABBV Bernstein -- Market Perform -- $203 Oct. 17, 2024

News

Final Trades: Abbvie, Boeing, Oracle and Joby Aviation
ABBV, BA, JOBY, ORCL
Published: July 10, 2025 by: CNBC Television
Sentiment: Neutral

The Investment Committee give you their top stocks to watch for the second half.

Read More
image for news Final Trades: Abbvie, Boeing, Oracle and Joby Aviation
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
ABBV, JNJ, LLY
Published: July 08, 2025 by: CNBC
Sentiment: Neutral

President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.

Read More
image for news Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
ABBV
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Neutral

ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.

Read More
image for news How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
ABBV
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
ABBV
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read More
image for news Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
AbbVie Stock At $190: Premium Pricing For A Transformation Story
ABBV
Published: July 02, 2025 by: Forbes
Sentiment: Positive

AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

Read More
image for news AbbVie Stock At $190: Premium Pricing For A Transformation Story
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
ABBV
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
ABBV
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Neutral

ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.

Read More
image for news Will AbbVie's Acquisition Spree Aid Pipeline Growth?
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
ABBV
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.

Read More
image for news ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
Abbvie confirms $2.1bn Capstan swoop
ABBV
Published: June 30, 2025 by: Proactive Investors
Sentiment: Positive

Abbvie Inc (NYSE:ABBV) has agreed to acquire Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases and gaining access to a new type of RNA delivery system. The acquisition will give the pharma giant control of CPTX2309, a lipid nanoparticle-based therapy that delivers mRNA directly into the body to program the immune system.

Read More
image for news Abbvie confirms $2.1bn Capstan swoop
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
ABBV
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.

Read More
image for news AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
Jim Cramer's Safest Stock For Retirees
ABBV
Published: June 26, 2025 by: 24/7 Wall Street
Sentiment: Positive

Jim Cramer has a mixed record when it comes to choosing stocks.

Read More
image for news Jim Cramer's Safest Stock For Retirees
Here's Why AbbVie (ABBV) is a Strong Momentum Stock
ABBV
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Here's Why AbbVie (ABBV) is a Strong Momentum Stock
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
ABBV
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
ABBV
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.

Read More
image for news Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
ABBV
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Negative

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.

Read More
image for news AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
ABBV
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Neutral

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Read More
image for news Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
Here's Why AbbVie (ABBV) is a Strong Value Stock
ABBV
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Here's Why AbbVie (ABBV) is a Strong Value Stock
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
ABBV, BAYRY, NVS, PFE, SNY
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral

In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.

Read More
image for news 5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
AbbVie says blood cancer drug fails late-stage trial
ABBV
Published: June 16, 2025 by: Reuters
Sentiment: Negative

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of overall survival in a late-stage trial.

Read More
image for news AbbVie says blood cancer drug fails late-stage trial
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
ABBV
Published: June 16, 2025 by: PRNewsWire
Sentiment: Neutral

NORTH CHICAGO, Ill. , June 16, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772.

Read More
image for news AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight
ABBV
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ's approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market. The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form …

Read More
image for news Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
ABBV
Published: June 11, 2025 by: PRNewsWire
Sentiment: Neutral

MAVYRET® (glecaprevir/pibrentasvir) is the first and only oral eight-week pangenotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV)* With this approval, providers can now treat HCV patients immediately at the time of diagnosis HCV is a curable condition, but patients can often go undiagnosed.1 If left untreated, people with acute HCV could progress to chronic disease, including liver-related complications, such as cirrhosis or liver cancer1 The approval supports global clinical guidelines to advance testing and treatment for people with HCV regardless of chronicity, and supports public health goals for disease elimination NORTH CHICAGO, Ill. , …

Read More
image for news U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
ABBV
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
ABBV
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.

Read More
image for news Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
ABBV
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.

Read More
image for news Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc. (ABBV)
ABBV
Published: June 04, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).

Read More
image for news Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc. (ABBV)
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
ABBV, AMGN, BSX, DXCM
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive

BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.

Read More
image for news Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
Bert's May 2025 Dividend Income Summary
ABBV, C, CZNC, KMI, NSC, O, PG, SBUX, T, TXN, VZ
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Negative

Our dividend income dropped by 15% in May. We had Healthpeak Properties change the structure of its dividend. June will be a very exciting month and I cannot wait to see the dividend distributions for our ETFs, especially SCHD.

Read More
image for news Bert's May 2025 Dividend Income Summary
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
ABBV
Published: June 03, 2025 by: PRNewsWire
Sentiment: Neutral

The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVie is committed to supporting the migraine community beyond treatment.

Read More
image for news AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals

About AbbVie Inc. (ABBV)

  • IPO Date 2013-01-02
  • Website https://www.abbvie.com
  • Industry Drug Manufacturers - General
  • CEO Robert A. Michael CPA
  • Employees 55000

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.